Compare · AZN vs TRAX
AZN vs TRAX
Side-by-side comparison of AstraZeneca PLC (AZN) and First Tracks Biotherapeutics Inc. (TRAX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and TRAX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $262.48B, about 211.8x TRAX ($1.24B).
- Over the past year, AZN is down 10.2% and TRAX is up 90.9% - TRAX leads by 101.1 points.
- AZN has hit the wire 7 times in the past 4 weeks while TRAX has been quiet.
- AZN has more recent analyst coverage (25 ratings vs 8 for TRAX).
- Company
- AstraZeneca PLC
- First Tracks Biotherapeutics Inc.
- Price
- $169.00+0.41%
- $35.46-5.62%
- Market cap
- $262.48B
- $1.24B
- 1M return
- -7.41%
- +113.23%
- 1Y return
- -10.25%
- +90.85%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- News (4w)
- 7
- 0
- Recent ratings
- 25
- 8
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Latest AZN
- Enhertu® Plus Pertuzumab Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- AstraZeneca downgraded by HSBC Securities
- SEC Form 6-K filed by AstraZeneca PLC
- Officer Sharma Mani was granted 2 units of Ordinary Shares, increasing direct ownership by 0.01% to 19,265 units (SEC Form 4)
- The Quantum Sector Hits an Inflection Point: Federal Money, Real Milestones, and a Security Race Running in Parallel
- Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
Latest TRAX
- First Tracks Biotherapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement
- Director Schmid John P. converted options into 6,030 shares, increasing direct ownership by 19% to 37,652 units (SEC Form 4)
- Director Marquet Magda converted options into 6,030 shares, increasing direct ownership by 61% to 15,960 units (SEC Form 4)
- Director Jain Rita converted options into 7,330 shares, increasing direct ownership by 62% to 19,194 units (SEC Form 4)
- Director Orwin John A converted options into 6,030 shares, increasing direct ownership by 57% to 16,695 units (SEC Form 4)
- Director Ware J. Anthony converted options into 6,030 shares, increasing direct ownership by 63% to 15,660 units (SEC Form 4)
- Director Fenton Dennis M converted options into 6,030 shares, increasing direct ownership by 121% to 10,995 units (SEC Form 4)
- Amendment: SEC Form 4 filed by Director Fenton Dennis M
- Amendment: SEC Form 4 filed by Director Jain Rita
- Amendment: SEC Form 4 filed by Director Marquet Magda